The global Label-Free Detection market is projected to reach US$1.3 billion by 2025, driven by growing drug R&D, rising competitive pressure to reduce cost of drug development and the resulting need for cost-effective and efficient screening technologies. Traditional label-based assays are beset with drawbacks such as high cost associated with label preparation; lower levels of sensitivity and accuracy as measurements are made indirectly using a labeled reactant; risk of certain antigen/antibody reactions not being detected; requires multiple steps and is time consuming; and tendency to modify the physicochemical or binding properties making accurate drug characterization difficult. In this regard, label-free assays for biochemical and cell-based drug discovery is growing in importance due to the many benefits offered such as ability to identify difficult target classes, better insights offered into drug binding kinetics and drug residence time; highly sensitive detection of small molecules, proteins and cells; simple assay procedure; less potential for false positive/negatives; eliminates labelling & reagent costs; aids in high-throughput, independent screening of whole cells; provides new insights into compound action and helps devise better optimization strategies; increased sensitivity and specificity; more accurate quantification of biological responses, among others. All of these benefits are helping replace traditional techniques like radioactive assays, enzyme-labelled assays (ELISA assays), fluorescent labeled assays, luminescent labeled assays, and Chemiluminescence immunoassay (CLIA) with label-free options.
Few of the major trends influencing growth in the market include growing population, rising disease burden and the need for new generation drugs and therapies; growing pressure on pharmaceutical companies to strengthen their drug pipelines against the backdrop of patent expiry, competition from generics and reduction in profits/revenues; increased government investment support for life sciences research to develop effective, safe and affordable drugs; growing interest in genomics research and proteomics; growing production of recombinant therapeutic proteins; expanding pharmaceutical contract research outsourcing and new opportunities in Asia-Pacific; growing market for biosimilars and increased need for label-free detection as an analytical tool to demonstrate biosimilarity; rising incidence of food allergy and the ensuing demand for label-free detection of allergens in food; and strong opportunity for label free detection in cancer diagnosis and characterization. The United States and Europe represent large markets worldwide with a combined share of 64.8%. China ranks as the fastest growing market with a 9.7% CAGR over the analysis period supported by the globalization of the countrys life sciences sector. The Chinese governments dedicated support of the industry has resulted in China developing innovative drug molecules for the domestic healthcare market. The country also plans to export Chinese-made pharmaceuticals. The recent approval of countrys first WHO-prequalified vaccine brightens the outlook for Chinese-made pharmaceuticals. The expected growth of the countrys life sciences sector and pharmaceutical R&D spending which is poised to reach over US$30 billion by 2020, bodes well for the adoption and growth of label-free detection. Asia-Pacific excluding China follows next with a 9.5% CAGR led by India, and other Southeast Asian countries.
Our reports have been used by over 10K customers, including:
Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (In-house, Contract Outsourcing), By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End Use, And Segment Forecasts, 2021 - 2028
Pharmacovigilance Market Growth & Trends
The global pharmacovigilance...
The Middle East and Africa medical writing market is expected to reach US$ 254.84 million by 2027 from US$ 156.02 million in 2019; it is anticipated to grow at a CAGR of 6.3% from 2020 to 2027. The growth of the Middle East and Africa medical writing market is driven by the high growth in research and development, and massive government...
The particle counters market is projected to grow at a CAGR of 9.9% during the forecast period, to reach USD 554million by 2025 from USD 346million in 2020. The growth in thismarket is driven by the robust growth in applied markets, the favorable regulatory scenario, and growing focus on the quality of food products. In addition, emerging...
C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2020
Summary
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes....
This IDC Perspective provides analyst insights on the growing importance of eCOAs, especially in the post-COVID-19 world. Despite the world being hit by a horrific pandemic, the pharma and biotech industry has risen to the occasion and leveraged digital transformation to bring trials to patients' homes. eCOAs drive "patient centric" clinical...
The mass spectrometry market size is expected to grow from an estimated USD 4.1 billion in 2020 to USD 5.6 billion by 2025, at a CAGR of 6.5%. Increasing spending on pharmaceutical R&D across the globe, government regulations on drug safety, growing focus on the quality of food products, increase in crude and shale gas production, and growing...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
The global flow imaging microscopy market size is projected to reach USD 45 million by 2025 from USD 32 million in 2020, at a CAGR of 7.4%. The growth of the market is attributed to increasing investment in the field of nanotechnology, growing investments in pharmaceutical R&D, and stringent regulatory guidelines for product quality across...
Pharmaceutical
Biotechnology
World
Europe
North America
APAC
Health Expenditure
Drug Approval
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.